Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

NCT01425749 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: recMAGE-A3 + AS15 ASCI

Sponsor

Craig L Slingluff, Jr

Collaborators

[object Object]